A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ

Key Findings:  Although clinical and preclinical studies suggest the endocannabinoid system (ECS) plays a role in the pathology of sleep disorders and Autism spectrum disorder (ASD), this randomized placebo-controlled trial of adolescents with ASD found that administration of cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (THC) at a 20:1 ratio did not improve sleep.

Type of Study:  Double Blind Clinical Trial

Study Sample Size:  150

Study Result:  Inconclusive

Study Location(s):  Israel

Year of Pub:  2022

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Cannabinoid (unspecified)

Phytocannabinoid Source:  Cannabis Flower derived

Chemotype:  Chemotype II, Chemotype III

Receptors Studied:  CB1, CB2, GPCR 55, TRPV1, PPAR - Gamma

Ligands Studied:  GABA, Serotonin

Route of Administration:  Oral (Ingestion)

Link to study